The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Effects of Nicotine on Cognitive Deficits in Schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Smoking, smoking cessation, and major depression
Glassman, A. H. (1990) · JAMA · doi:10.1001/jama.1990.03450120058029 · Cited by 1,207
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · cited 1×
“The gene for the alpha7 nicotinic receptor is associated with schizophrenia, but not particularly with smoking behavior (Freedman et al, 1997).”
BackgroundSelf-citationFreedman, R., Hall, M., Adler, L. E., & Leonard, S. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(94)00252-x · Cited by 678 · cited 1×
“Reduced numbers of nicotinic receptors have been identified in the post-mortem brains of schizophrenic patients compared with controls (Marutle et al, 2001; Guan et al, 1999; Court et al, 1999; Freedman et al, 1995).”
BackgroundSelf-citationThe nature of learning and memory impairments in schizophrenia
Paulsen, J. S., Heaton, R. K., Sadek, J. R., Perry, W., Delis, D. C., Braff, D., Kuck, J., Zisook, S., & Jeste, D. V. (1995) · Journal of the International Neuropsychological Society · doi:10.1017/s135561770000014x · Cited by 284
Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia
Marutle, A., Zhang, X., Court, J., Piggott, M., Johnson, M., Perry, R., Perry, E., & Nordberg, A. (2001) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(01)00117-x · Cited by 175
Cited by
Levin, E. D., McClernon, F. J., & Rezvani, A. H. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0164-7 · Cited by 820
Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report
Ziedonis, D., Hitsman, B., Beckham, J. C., Zvolensky, M., Adler, L. E., Audrain-McGovern, J., Breslau, N., Brown, R. A., George, T. P., Williams, J., et al. (2008) · Nicotine & Tobacco Research · doi:10.1080/14622200802443569 · Cited by 735
Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia
Olincy, A., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 527
Self-citationNicotine use in schizophrenia: The self medication hypotheses
Kumari, V., & Postma, P. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.02.006 · Cited by 468
Hurst, R. S., Hajós, M., Raggenbass, M., Wall, T. M., Higdon, N. R., Lawson, J. A., Rutherford-Root, K. L., Berkenpas, M. B., Hoffmann, W. E., Piotrowski, D. W., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5269-04.2005 · Cited by 446
Initial phase 2 trial of a nicotinic agonist in schizophrenia
Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07071135 · Cited by 426
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Nicotine addiction and comorbidity with alcohol abuse and mental illness
Dani, J. A., & Harris, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1580 · Cited by 382
Sacco, K. A., Termine, A., Seyal, A., Dudas, M. M., Vessicchio, J. C., Krishnan-Sarin, S., Jatlow, P. I., Wexler, B. E., & George, T. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.649 · Cited by 330
Schizophrenia and the α7 Nicotinic Acetylcholine Receptor
Martin, L. F., & Freedman, R. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78008-4 · Cited by 213
Self-citationEvins, A. E., Cather, C., Culhane, M. A., Birnbaum, A., Horowitz, J., Hsieh, E., Freudenreich, O., Henderson, D. C., Schoenfeld, D. A., Rigotti, N. A., et al. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0b013e3180ca86fa · Cited by 179
“Lowaffinity nicotinic receptors desensitize rapidly,(35) and increased nicotinic transmission with long acting NRT may be limited by tachyphylaxis at these receptors.(36) However, nicotine seems to improve sensory gating deficits and attention deficits in schizophrenia by improving inhibition of responses to sensory i…”
BackgroundGalantamine for the treatment of cognitive impairments in people with schizophrenia
Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050724 · Cited by 170
Wilens, T. E., & Decker, M. W. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.002 · Cited by 164
Levin, E. D., & Rezvani, A. H. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.019 · Cited by 129
“Nicotine also improves eye tracking, memory and attentional function in schizophrenia [84,85,88,92].”
BackgroundSmoking impacts on prefrontal attentional network function in young adult brains
Musso, F., Bettermann, F., Vucurevic, G., Stoeter, P., Konrad, A., & Winterer, G. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0499-8 · Cited by 93
“Among the best described effects of nicotine on cognition is its positive impact on vigilance and attention both in animal models and in smoking and nonsmoking humans (Adan et al. 2004; Edwards et al. 1985; Hahn et al. 2002, 2003; Harris et al. 2004; Houlihan et al. 1996a,b; Muir et al. 1994; Rezvani and Levin 2001; S…”
BackgroundThe effects of arousal on apical amplification and conscious state
Phillips, W. A., Larkum, M. E., Harley, C. W., & Silverstein, S. M. (2016) · Neuroscience of Consciousness · doi:10.1093/nc/niw015 · Cited by 75
Barbier, A. J., Hilhorst, M., Vliet, A. V., Snyder, P., Palfreyman, M. G., Gawryl, M., Dgetluck, N., Massaro, M., Tiessen, R., Timmerman, W., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.013 · Cited by 51
“Age, y Mean (SD) 25 (6) 23 (4) 31 (10) 27 (8) 22 (2) 21 (2) 26 (7) Range 19 41 18 31 20 44 20 42 20 26 19 26 20 41 Height, cm Mean (SD) 181 (5) 187 (6) 180 (5) 181 (8) 186 (3) 184 (5) 179 (6) Range 171 188 179 195 174 185 168 193 182 189 177 191 170 189 Weight, kg Mean (SD) 78.”
BackgroundDeficits in auditory P50 inhibition in obsessive-compulsive disorder
Hashimoto, T., Shimizu, E., Koike, K., Orita, Y., Suzuki, T., Kanahara, N., Matsuzawa, D., Fukami, G., Miyatake, R., Shinoda, N., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.021 · Cited by 41
Acetylcholinesterase inhibitors may improve myelin integrity
Bartzokis, G. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.020 · Cited by 41
Pharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Metadata
- Authors
- Harris, J. G., Kongs, S., Allensworth, D., Martin, L., Tregellas, J., Sullivan, B., Zerbe, G., & Freedman, R.
- Venue
- Neuropsychopharmacology
- Published
- 2004-05-12
- Volume
- 29
- Issue
- 7
- Pages
- 1378-1385
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2084399151
- Cited by
- 237
- References
- 6
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.